Access Research Institute

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials
• Chronic kidney disease2 trials
• Crohn's disease2 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Gout2 trials
• Chronic spontaneous urticaria1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Depression1 trial
• Liver cirrhosis1 trial
• Peripheral artery disease1 trial

Phase

• Phase 37 trials
• Phase 2/33 trials
• Phase 22 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting4 trials
• Active, not recruiting3 trials
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Atom Therapeutics Co., Ltd2 trials
• Boehringer Ingelheim2 trials
• Hoffmann-La Roche2 trials
• Abivax S.A.1 trial
• CSL Behring1 trial
• and 5 more

Running trials

• Recruiting

  A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  NCT06581328· Phase 4· Takeda· Source

  Contact: Salman Muddassir (principal investigator)

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate Solrikitug in Participants With COPD (ZION)

  NCT06496620· Phase 2· Uniquity One (UNI)· Source

• Active, not recruiting

  To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

  NCT05908084· Phase 3· Humacyte, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Liver cirrhosis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

  Contact: Trial Registration Coordinator

• Terminated

  Extension Study of ABP-671 in Participants With Gout

  NCT06276556· Phase 2/3· Atom Therapeutics Co., Ltd· Source

• Completed

  Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

  NCT05774639· Phase 3· Kashiv BioSciences, LLC· Source

• Completed

  Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

  NCT05818085· Phase 2/3· Atom Therapeutics Co., Ltd· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Denovo Biopharma LLC· Source